KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biomarin Pharmaceutical (BMRN) Cost of Revenue (2017 - 2025)

Biomarin Pharmaceutical (BMRN) has disclosed Cost of Revenue for 15 consecutive years, with $275.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cost of Revenue rose 102.52% year-over-year to $275.7 million, compared with a TTM value of $717.4 million through Dec 2025, up 23.65%, and an annual FY2025 reading of $717.4 million, up 23.65% over the prior year.
  • Cost of Revenue was $275.7 million for Q4 2025 at Biomarin Pharmaceutical, up from $140.1 million in the prior quarter.
  • Across five years, Cost of Revenue topped out at $275.7 million in Q4 2025 and bottomed at $103.5 million in Q3 2021.
  • Average Cost of Revenue over 5 years is $140.2 million, with a median of $130.5 million recorded in 2023.
  • The sharpest move saw Cost of Revenue tumbled 45.16% in 2021, then soared 102.52% in 2025.
  • Year by year, Cost of Revenue stood at $119.8 million in 2021, then increased by 22.46% to $146.6 million in 2022, then dropped by 5.94% to $137.9 million in 2023, then fell by 1.3% to $136.1 million in 2024, then surged by 102.52% to $275.7 million in 2025.
  • Business Quant data shows Cost of Revenue for BMRN at $275.7 million in Q4 2025, $140.1 million in Q3 2025, and $150.1 million in Q2 2025.